These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

416 related articles for article (PubMed ID: 34093873)

  • 1. Genomic and transcriptional alterations in first-line chemotherapy exert a potentially unfavorable influence on subsequent immunotherapy in NSCLC.
    He Y; Chen L; Zhao L; Dang S; Liu G; Sasada S; Ma PC; van Zandwijk N; Rosell R; Popper HH; Wang H; Jiang M; Guo H; Liu X; Chen S; Zhang X; Xu M; Zhu B; Liu M; Zhou C
    Theranostics; 2021; 11(14):7092-7109. PubMed ID: 34093873
    [No Abstract]   [Full Text] [Related]  

  • 2. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of Blood Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Patients With Non-Small Cell Lung Cancer With Use of a Next-Generation Sequencing Cancer Gene Panel.
    Wang Z; Duan J; Cai S; Han M; Dong H; Zhao J; Zhu B; Wang S; Zhuo M; Sun J; Wang Q; Bai H; Han J; Tian Y; Lu J; Xu T; Zhao X; Wang G; Cao X; Li F; Wang D; Chen Y; Bai Y; Zhao J; Zhao Z; Zhang Y; Xiong L; He J; Gao S; Wang J
    JAMA Oncol; 2019 May; 5(5):696-702. PubMed ID: 30816954
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Zhang N; Shen J; Gou L; Cao M; Ding W; Luo P; Zhang J
    Bioengineered; 2022 May; 13(5):11577-11592. PubMed ID: 35531878
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular heterogeneity of anti-PD-1/PD-L1 immunotherapy efficacy is correlated with tumor immune microenvironment in East Asian patients with non-small cell lung cancer.
    Jin R; Liu C; Zheng S; Wang X; Feng X; Li H; Sun N; He J
    Cancer Biol Med; 2020 Aug; 17(3):768-781. PubMed ID: 32944405
    [No Abstract]   [Full Text] [Related]  

  • 6. Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing.
    Rizvi H; Sanchez-Vega F; La K; Chatila W; Jonsson P; Halpenny D; Plodkowski A; Long N; Sauter JL; Rekhtman N; Hollmann T; Schalper KA; Gainor JF; Shen R; Ni A; Arbour KC; Merghoub T; Wolchok J; Snyder A; Chaft JE; Kris MG; Rudin CM; Socci ND; Berger MF; Taylor BS; Zehir A; Solit DB; Arcila ME; Ladanyi M; Riely GJ; Schultz N; Hellmann MD
    J Clin Oncol; 2018 Mar; 36(7):633-641. PubMed ID: 29337640
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of Tumor Mutational Burden With DNA Repair Mutations and Response to Anti-PD-1/PD-L1 Therapy in Non-Small-Cell Lung Cancer.
    Chae YK; Davis AA; Raparia K; Agte S; Pan A; Mohindra N; Villaflor V; Giles F
    Clin Lung Cancer; 2019 Mar; 20(2):88-96.e6. PubMed ID: 30425022
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Robust Prediction of Immune Checkpoint Inhibition Therapy for Non-Small Cell Lung Cancer.
    Jiang J; Jin Z; Zhang Y; Peng L; Zhang Y; Zhu Z; Wang Y; Tong D; Yang Y; Wang J; Yang Y; Xiao K
    Front Immunol; 2021; 12():646874. PubMed ID: 33927719
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
    Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
    Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
    [No Abstract]   [Full Text] [Related]  

  • 10. Paired analysis of tumor mutation burden calculated by targeted deep sequencing panel and whole exome sequencing in non-small cell lung cancer.
    Park S; Lee C; Ku BM; Kim M; Park WY; Kim NKD; Ahn MJ
    BMB Rep; 2021 Jul; 54(7):386-391. PubMed ID: 34154699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune suppressive microenvironment in liver metastases contributes to organ-specific response of immunotherapy in advanced non-small cell lung cancer.
    Deng JY; Gou Q; Yang L; Chen ZH; Yang MY; Yang XR; Yan HH; Wei XW; Liu JQ; Su J; Zhong WZ; Xu CR; Wu YL; Zhou Q
    J Immunother Cancer; 2023 Jul; 11(7):. PubMed ID: 37463790
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of cytotoxic chemotherapy on PD-L1 expression in patients with non-small cell lung cancer negative for EGFR mutation and ALK fusion.
    Sakai H; Takeda M; Sakai K; Nakamura Y; Ito A; Hayashi H; Tanaka K; Nishio K; Nakagawa K
    Lung Cancer; 2019 Jan; 127():59-65. PubMed ID: 30642552
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of platinum-based chemotherapy on the tumor mutational burden and immune microenvironment in non-small cell lung cancer with postoperative recurrence.
    Wu J; Sun W; Zhang Y; Mao L; Ding T; Huang X; Lin D
    Clin Transl Oncol; 2024 Jul; 26(7):1738-1747. PubMed ID: 38421562
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer.
    Negrao MV; Skoulidis F; Montesion M; Schulze K; Bara I; Shen V; Xu H; Hu S; Sui D; Elamin YY; Le X; Goldberg ME; Murugesan K; Wu CJ; Zhang J; Barreto DS; Robichaux JP; Reuben A; Cascone T; Gay CM; Mitchell KG; Hong L; Rinsurongkawong W; Roth JA; Swisher SG; Lee J; Tsao A; Papadimitrakopoulou V; Gibbons DL; Glisson BS; Singal G; Miller VA; Alexander B; Frampton G; Albacker LA; Shames D; Zhang J; Heymach JV
    J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34376553
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of Patient Characteristics and Tumor Genomics With Clinical Outcomes Among Patients With Non-Small Cell Lung Cancer Using a Clinicogenomic Database.
    Singal G; Miller PG; Agarwala V; Li G; Kaushik G; Backenroth D; Gossai A; Frampton GM; Torres AZ; Lehnert EM; Bourque D; O'Connell C; Bowser B; Caron T; Baydur E; Seidl-Rathkopf K; Ivanov I; Alpha-Cobb G; Guria A; He J; Frank S; Nunnally AC; Bailey M; Jaskiw A; Feuchtbaum D; Nussbaum N; Abernethy AP; Miller VA
    JAMA; 2019 Apr; 321(14):1391-1399. PubMed ID: 30964529
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Smoking status combined with tumor mutational burden as a prognosis predictor for combination immune checkpoint inhibitor therapy in non-small cell lung cancer.
    Sun LY; Cen WJ; Tang WT; Long YK; Yang XH; Ji XM; Yang JJ; Zhang RJ; Wang F; Shao JY; Du ZM
    Cancer Med; 2021 Oct; 10(19):6610-6617. PubMed ID: 34469045
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Predictive Value of PAK7 Mutation for Immune Checkpoint Inhibitors Therapy in Non-Small Cell Cancer.
    Zeng H; Tong F; Bin Y; Peng L; Gao X; Xia X; Yi X; Dong X
    Front Immunol; 2022; 13():834142. PubMed ID: 35242138
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the somatic genomic landscape between central- and peripheral-type non-small cell lung cancer.
    Wang L; Diao M; Zhang Z; Jiang M; Chen S; Zhao D; Liu Z; Zhou C
    Lung Cancer; 2024 Jan; 187():107439. PubMed ID: 38113653
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genomic scoring to determine clinical benefit of immunotherapy by targeted sequencing.
    Kim HS; Cha H; Kim J; Park WY; Choi YL; Sun JM; Ahn JS; Ahn MJ; Park K; Lee SH
    Eur J Cancer; 2019 Oct; 120():65-74. PubMed ID: 31493723
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel tumor mutational burden estimation model as a predictive and prognostic biomarker in NSCLC patients.
    Tian Y; Xu J; Chu Q; Duan J; Zhang J; Bai H; Yang Z; Fang W; Cai L; Wan R; Fei K; He J; Gao S; Zhang L; Wang Z; Wang J
    BMC Med; 2020 Aug; 18(1):232. PubMed ID: 32843031
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.